Steven P. Treon

Steven P. Treon, MD, MA, PhD, is Professor of Medicine at Harvard Medical School and Attending Physician at Dana-Farber Cancer Institute, where he serves as founding Director of the Bing Center for Waldenström’s Macroglobulinemia. He leads a multidisciplinary program integrating bench-to-bedside research focused on Waldenström macroglobulinemia, multiple myeloma, and, more recently, COVID-19 therapeutics leveraging BTK inhibitors.

Research Interests:

• Waldenström macroglobulinemia biology, genomics, and targeted therapy
• Multiple myeloma immunotherapy and clinical trial design
• Mechanisms of BTK inhibition in B-cell malignancies
• Repurposing ibrutinib for COVID-19–associated pulmonary injury
• Translational precision medicine in lymphoproliferative disorders

His recent 2020 publications center on the protective effects of the BTK inhibitor ibrutinib against COVID-19–related lung injury, featuring a series of clinical observations and the launch of a randomized trial. These works bridge oncology and infectious-disease research, highlighting his innovative approach to drug repositioning.

Scientific Awards & Honors:
No specific awards are listed in the provided text.

Advising & Funding:
While no individual advisees are named, Dr. Treon leads the Bing Center for Waldenström's, mentoring numerous fellows and junior faculty. Ongoing clinical-trial funding supports his COVID-19 ibrutinib study (NCT04375397) and multiple myeloma workshops.

Laboratory & Teams:
He directs the Bing Center for Waldenström’s Macroglobulinemia at Dana-Farber Cancer Institute, coordinating a collaborative team of translational researchers, clinical investigators, and data scientists.